Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 15/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

133%

4 of 3 completed with results

Key Signals

4 with results100% success

Data Visualizations

Phase Distribution

4Total

P 2 (3)

P 3 (1)

Trial Status

Completed3

Unknown1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (4)

Showing 4 of 4 trials

NCT00492778Phase 2UnknownPrimary

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

NCT01210222Phase 2Completed

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

NCT00064025Phase 2Completed

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

NCT00006011Phase 3Completed

Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

Showing all 4 trials

Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation